D6 Building 1 Thane Road
Nottingham NG90 6BH
44 1157 840 500
|Dr. Adam Mark Hill Ph.D.||CEO & Director||439k||N/A||1980|
|Mr. Matthew Hall||Chief Financial Officer||N/A||N/A||N/A|
|Prof. Tariq Sethi M.D., B.Sc., M.A., Ph.D., FRCP||Chief Scientific Officer||N/A||N/A||N/A|
|Ms. Cléa Rosenfeld||Head of Investor Relations||N/A||N/A||N/A|
|Mr. Ron Kirschner||Gen. Counsel & Company Sec.||N/A||N/A||N/A|
|Mr. Maarten Brusse||Chief Commercial Officer of Asia||N/A||N/A||N/A|
|Mr. Cameron Barnard||Chief Bus. Officer||N/A||N/A||N/A|
Oncimmune Holdings plc develops and commercializes technologies that enable cancer diagnosis in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, a immunodiagnostic test for detecting and identifying lung cancer. The company also develops SeroTag, a platform that is used to discover and validate biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel. Oncimmune Holdings plc has a collaboration with Siemens Healthineers AG. Oncimmune Holdings plc was incorporated in 2015 and is based in Nottingham, the United Kingdom.
Oncimmune Holdings Plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.